Movement Disorders

Michelle E. Fullard, Sharon X. Xie, Ken Marek, Matthew Stern, Danna Jennings, Andrew Siderowf, Allison W. Willis, Alice S. Chen-Plotkin September 14, 2017

ABSTRACT

Background

Lower vitamin D levels have been associated with manifest Parkinson’s disease, prompting the hypothesis that vitamin D insufficiency or deficiency may increase risk for PD.

Objectives

To evaluate vitamin D levels in a population at risk for developing PD.

Read More...
Chris Frost, Amy Mulick, Rachael I. Scahill, Gail Owen, Elizabeth Aylward, Blair R. Leavitt, Alexandra Durr, Raymund A. C. Roos, Beth Borowsky, Julie C. Stout, Ralf Reilmann, Douglas R. Langbehn, Sarah J. Tabrizi, Cristina Sampaio, September 14, 2017

ABSTRACT

Objectives

The purpose of this study was to inform the design of randomized clinical trials in early-stage manifest Huntington’s disease through analysis of longitudinal data from TRACK-Huntington’s Disease (TRACK-HD), a multicenter observational study.

Methods

We compute sample sizes required for trials with candidate clinical, functional, and imaging outcomes, whose aims are to reduce rates of change.

Read More...
Sebastian R. Schreglmann, Franz Riederer, Marian Galovic, Christos Ganos, Georg Kägi, Daniel Waldvogel, Zane Jaunmuktane, Andre Schaller, Ute Hidding, Ernst Krasemann, Lars Michels, Christian R. Baumann, Kailash Bhatia, Hans H. Jung September 13, 2017

ABSTRACT

Background: Mitochondrial disease can present as a movement disorder. Data on this entity’s epidemiology, genetics, and underlying pathophysiology, however, is scarce.

Objective: The objective of this study was to describe the clinical, genetic, and volumetric imaging data from patients with mitochondrial disease who presented with movement disorders.

Read More...
Elisa Frisaldi, Elisa Carlino, Maurizio Zibetti, Diletta Barbiani, Francesca Dematteis, Michele Lanotte, Leonardo Lopiano, Fabrizio Benedetti September 12, 2017

Abstract

Background: Placebo effects represent a major drawback in clinical trials, and their magnitude hampers the development of new treatments. Previous research showed that prior exposure to active treatments increases the placebo response for muscle rigidity in Parkinson’s disease.

Methods: We investigated the effects of prior exposure to apomorphine on the placebo response of another cardinal symptom of Parkinson’s disease, bradykinesia, by a movement time analyzer.

Read More...

Andoird App
Loading...